1. Home
  2. WAL vs DVAX Comparison

WAL vs DVAX Comparison

Compare WAL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Alliance Bancorporation (DE)

WAL

Western Alliance Bancorporation (DE)

HOLD

Current Price

$85.61

Market Cap

8.7B

Sector

Finance

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$15.38

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAL
DVAX
Founded
1994
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7B
1.3B
IPO Year
2005
2004

Fundamental Metrics

Financial Performance
Metric
WAL
DVAX
Price
$85.61
$15.38
Analyst Decision
Strong Buy
Hold
Analyst Count
14
5
Target Price
$99.64
$26.50
AVG Volume (30 Days)
866.2K
3.6M
Earning Date
01-26-2026
11-05-2025
Dividend Yield
1.78%
N/A
EPS Growth
24.99
N/A
EPS
8.09
N/A
Revenue
$3,189,400,000.00
$330,514,000.00
Revenue This Year
$16.21
$24.63
Revenue Next Year
$9.07
$15.85
P/E Ratio
$10.55
N/A
Revenue Growth
9.57
26.73
52 Week Low
$57.05
$9.20
52 Week High
$94.40
$15.49

Technical Indicators

Market Signals
Indicator
WAL
DVAX
Relative Strength Index (RSI) 53.98 88.91
Support Level $85.14 $10.78
Resistance Level $88.09 $15.49
Average True Range (ATR) 2.01 0.20
MACD -0.23 0.52
Stochastic Oscillator 42.78 97.63

Price Performance

Historical Comparison
WAL
DVAX

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: